{"id":"NCT03915860","sponsor":"Galderma R&D","briefTitle":"Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris","officialTitle":"A Multi-Center Study to Evaluate Subject Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-27","primaryCompletion":"2019-12-23","completion":"2019-12-23","firstPosted":"2019-04-16","resultsPosted":"2021-12-15","lastUpdate":"2021-12-15"},"enrollment":47,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Trifarotene","otherNames":[]}],"arms":[{"label":"Trifarotene","type":"EXPERIMENTAL"}],"summary":"Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris","primaryOutcome":{"measure":"Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24","timeFrame":"Baseline, Week 12 and Week 24","effectByArm":[{"arm":"Trifarotene","deltaMin":-1.8,"sd":2.97}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Application site pain","Application site dermatitis","Sunburn"]}}